Media Alert: BrainChip Details Olfactory Capabilities of Identifying Bacteria in the Blood in New Research Report

Rhea-AI Summary

BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY) announces the availability of a research paper detailing the use of neuromorphic computing in an electric nose system to detect and identify bacteria in the blood. The study shows that their hardware-driven neuromorphic solution, combined with electronic sensors, can accurately identify ten different bacteria species in blood samples with a classification accuracy of 97.42%, outperforming previous implementations. This breakthrough has the potential to revolutionize disease diagnosis, particularly in remote locations or outside traditional clinical facilities.

Positive

• The research paper demonstrates the potential of BrainChip's neuromorphic technology in healthcare applications, showcasing its ability to provide cost-effective, portable, and accurate solutions for disease diagnosis. The high classification accuracy of 97.42% is a significant achievement, outperforming previous implementations and indicating the effectiveness of the technology in identifying bacteria in blood samples.

Negative

• None.

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI IP, today announced the availability of a research paper detailing how neuromorphic computing can be utilized as part of an electric nose system to detect and identify different bacteria in the blood.

With findings achieved through studies by BrainChip Research, “Finding Bacteria in the Blood: Scaling a Hardware-Driven Neuromorphic Solution for Real-World E-Nose Applications” presents how a hardware-based, low-power neuromorphic solution can be combined with electronic sensors to create compelling real-world healthcare solutions that are cost-effective, portable and accurate. These assisted devices could significantly speed up disease diagnosis in remote locations, or even outside of traditional clinical facilities.

The paper explores a blood dataset collected as part of the Mednose project at Örebro University. The classifier model developed using Akida™ was able to identify ten different bacteria species in blood samples with a classification accuracy of 97.42%, outperforming previous implementations.

“Leveraging neuromorphic hardware to provide portable, power-efficient solutions for use in the identification of sensory data is a game-changer for a plethora of practical applications, such as e-nose systems,” said Anup Vanarse, Research Scientist at BrainChip. “This latest research paper shows how Akida’s olfactory analysis technology allows for efficient and accurate detection of various strains of bacteria in blood to help with important disease diagnosis. Incorporating beneficial AI within sensory devices will provide the means for massive breakthroughs in the healthcare industry.”

Those interested in reading more about neuromorphic solutions utilized in e-nose applications can download the full research paper at https://brainchip.com/finding-bacteria-in-blood

About BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY)

BrainChip is the worldwide leader in Edge AI on-chip processing and learning. The company’s first-to-market, fully digital, event-based AI processor, Akida^TM, uses neuromorphic principles to mimic the human brain, analyzing only essential sensor inputs at the point of acquisition, processing data with unparalleled efficiency, precision, and economy of energy. Akida uniquely enables Edge learning local to the chip, independent of the cloud, dramatically reducing latency while improving privacy and data security. Akida Neural processor IP, which can be integrated into SoCs on any process technology, has shown substantial benefits on today’s workloads and networks, and offers a platform for developers to create, tune and run their models using standard AI workflows like Tensorflow/Keras. In enabling effective Edge compute to be universally deployable across real world applications such as connected cars, consumer electronics, and industrial IoT, BrainChip is proving that on-chip AI, close to the sensor, is the future, for its customers’ products, as well as the planet. Explore the benefits of Essential AI at www.brainchip.com.

Follow BrainChip on Twitter: https://www.twitter.com/BrainChip_inc

Follow BrainChip on LinkedIn: https://www.linkedin.com/company/7792006

View source version on businesswire.com: https://www.businesswire.com/news/home/20231129515377/en/

Media Contact:

Mark Smith

JPR Communications

818-398-1424

Investor Contact:

Tony Dawe

Director, Global Investor Relations

BrainChip

tdawe@brainchip.com

Source: BrainChip Holdings Ltd

FAQ

How does BrainChip's technology contribute to disease diagnosis?

The research paper details how BrainChip's neuromorphic technology, combined with electronic sensors, can accurately identify ten different bacteria species in blood samples, with a classification accuracy of 97.42%, potentially revolutionizing disease diagnosis.

What is the focus of the research paper by BrainChip Holdings Ltd?

The research paper focuses on the utilization of neuromorphic computing in an electric nose system to detect and identify bacteria in the blood, showcasing the potential for revolutionizing disease diagnosis in remote locations.

What are the key findings of the research paper?

The research paper demonstrates that BrainChip's hardware-driven neuromorphic solution, combined with electronic sensors, can accurately identify ten different bacteria species in blood samples with a classification accuracy of 97.42%, outperforming previous implementations.

How does the research paper impact the healthcare industry?

The research paper indicates the potential for massive breakthroughs in the healthcare industry by providing cost-effective, portable, and accurate solutions for disease diagnosis, particularly in remote locations or outside traditional clinical facilities.